Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778176 | 0.80 | MALT1 (0.34) | HSD11B1PTPN11MALT1TRPV1 | |
| SCHEMBL7396450 | 0.79 | HSD11B1 (0.45) | HSD11B1PTPN11MALT1TRPV1DPP4 | |
| SCHEMBL1350753 | 0.78 | MALT1 (0.50) | HSD11B1PTPN11MALT1TRPV1 | |
| Hydrochloric Acid SCHEMBL9005364 | 0.78 | HSD11B1 (0.44) | HSD11B1PTPN11MALT1TRPV1DPP4 | |
| SCHEMBL1350750 | 0.78 | MALT1 (0.50) | HSD11B1PTPN11MALT1TRPV1 | |
| SCHEMBL931726 | 0.77 | MALT1 (0.56) | HSD11B1MALT1TRPV1TRPA1 | |
| SCHEMBL4635503 | 0.76 | KDM4E (0.54) | HSD11B1DPP4 | |
| SCHEMBL4320157 | 0.76 | EPHX2 (0.56) | HSD11B1TRPV1DPP4 | |
| SCHEMBL4871696 | 0.75 | CHRNB2 (0.50) | HSD11B1PTPN11MALT1TRPV1 | |
| SCHEMBL20283136 | 0.75 | HSD11B1 (0.48) | HSD11B1MALT1TRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | HSD11B1 251/4885PTPN11 2188/4885MALT1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.